Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.41 |
| ▸ | F10 | P00742 | 11/20 | 0.38 |
| ▸ | FASN | P49327 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL796596 | 1.00 | NAMPT (0.41) | NAMPTF10FASNCYP3A4CYP2D6 | |
| SCHEMBL11803522 | 0.77 | CD38 (0.43) | NAMPTCYP2D6 | |
| SCHEMBL5650400 | 0.76 | CYP2B6 (0.45) | NAMPTCYP2D6 | |
| SCHEMBL1614536 | 0.75 | KDM4E (0.37) | NAMPTALDH1A1 | |
| SCHEMBL13097363 | 0.74 | NAMPT (0.43) | NAMPT | |
| SCHEMBL11909339 | 0.73 | HPGD (0.45) | F10FASNALDH1A1 | |
| SCHEMBL15081807 | 0.72 | NAMPT (0.57) | NAMPT | |
| SCHEMBL4375626 | 0.71 | HDAC3 (0.56) | — | |
| SCHEMBL4038928 | 0.70 | HTR2A (0.44) | ALDH1A1 | |
| SCHEMBL13096895 | 0.70 | FAAH (0.51) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616071-A2 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2013-07-04 | — | — | US | disclosed |
| WO-2012037299-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | NAMPT 387/4885F10 2774/4885FASN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.